​

Twist Bioscience (TWST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TWST Stock Forecast

Twist Bioscience (TWST) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $43.33, with a high of $46.00 and a low of $40.00. This represents a 29.07% increase from the last price of $33.57.

$30 $36 $42 $48 $54 $60 High: $46 Avg: $43.33 Low: $40 Last Closed Price: $33.57

TWST Stock Rating

Twist Bioscience stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (76.92%), 2 Hold (15.38%), 1 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 2 10 0 Strong Sell Sell Hold Buy Strong Buy

TWST Price Target Upside V Benchmarks

TypeNameUpside
StockTwist Bioscience29.07%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks8.42%

Price Target Trends

1M3M12M
# Anlaysts126
Avg Price Target$40.00$43.00$48.67
Last Closing Price$33.57$33.57$33.57
Upside/Downside19.15%28.09%44.98%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25161--8
Sep, 25161-19
Aug, 25262-111
Jul, 25262-111
Jun, 25362-112
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 02, 2025Barclays$40.00$29.2636.71%19.15%
Aug 04, 2025Evercore ISI$46.00$30.2152.27%37.03%
May 06, 2025Catherine Ramsey SchulteRobert W. Baird$44.00$32.7534.35%31.07%
Mar 28, 2025Guggenheim$50.00$40.3623.89%48.94%
Feb 04, 2025Catherine Ramsey SchulteRobert W. Baird$54.00$52.023.81%60.86%
Feb 03, 2025Luke SergottBarclays$58.00$52.759.95%72.77%
Sep 17, 2024Catherine SchulteRobert W. Baird$46.00$48.18-4.52%37.03%
Jun 05, 2024Subbu NambiGuggenheim$53.00$46.9812.81%57.88%
May 03, 2024Catherine Ramsey SchulteRobert W. Baird$40.00$32.0124.96%19.15%
Jan 17, 2024Matthew SykesGoldman Sachs$45.00$34.8429.16%34.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 04, 2025Cowen & Co.BuyBuyhold
Feb 04, 2025ScotiabankOutperformOutperformhold
Feb 03, 2025BarclaysOverweightOverweighthold
Nov 18, 2024Cowen & Co.BuyBuyhold
Oct 01, 2024Evercore ISIOutperformOutperformhold
Aug 06, 2024ScotiabankOutperformOutperformhold
Jun 28, 2024BarclaysOverweightOverweighthold
Jun 13, 2024Cowen & Co.BuyBuyhold
Jun 04, 2024BarclaysOverweightOverweighthold
Jun 04, 2024GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-3.15$-4.04$-3.60$-3.60-----
Avg Forecast$-3.14$-4.47$-3.72$-3.72$-2.25$-1.66$-1.08$-0.49$0.04
High Forecast$-2.98$-3.57$-3.66$-3.70$-2.09$-1.50$-0.64$-0.48$0.04
Low Forecast$-3.31$-5.36$-3.76$-3.73$-2.35$-1.84$-1.85$-0.49$0.04
Surprise %0.32%-9.62%-3.23%-3.23%-----

Revenue Forecast

$100M $230M $360M $490M $620M $750M Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$132.33M$203.56M$245.11M$312.97M-----
Avg Forecast$130.95M$179.37M$241.58M$310.91M$373.27M$438.47M$522.91M$605.50M$708.05M
High Forecast$136.44M$215.25M$242.01M$311.41M$375.62M$440.20M$524.65M$610.70M$714.14M
Low Forecast$125.78M$143.50M$240.00M$310.12M$372.11M$434.79M$521.17M$597.70M$698.93M
Surprise %1.06%13.49%1.46%0.66%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-152.10M$-217.86M$-204.62M$-208.73M-----
Avg Forecast$-164.95M$-214.13M$-205.80M$-215.37M$-128.91M$-96.84M$-80.93M$-28.14M$2.32M
High Forecast$-131.96M$-171.31M$-164.64M$-214.51M$-121.43M$-86.98M$-37.20M$-27.67M$2.35M
Low Forecast$-197.93M$-256.96M$-246.96M$-216.24M$-136.39M$-106.70M$-107.50M$-28.45M$2.28M
Surprise %-7.79%1.74%-0.58%-3.09%-----

TWST Forecast FAQ

Is Twist Bioscience stock a buy?

Twist Bioscience stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Twist Bioscience is a favorable investment for most analysts.

What is Twist Bioscience's price target?

Twist Bioscience's price target, set by 13 Wall Street analysts, averages $43.33 over the next 12 months. The price target range spans from $40 at the low end to $46 at the high end, suggesting a potential 29.07% change from the previous closing price of $33.57.

How does Twist Bioscience stock forecast compare to its benchmarks?

Twist Bioscience's stock forecast shows a 29.07% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (8.42%).

What is the breakdown of analyst ratings for Twist Bioscience over the past three months?

  • October 2025: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.
  • August 2025: 18.18% Strong Buy, 54.55% Buy, 18.18% Hold, 0% Sell, 9.09% Strong Sell.

What is Twist Bioscience’s EPS forecast?

Twist Bioscience's average annual EPS forecast for its fiscal year ending in September 2025 is $-2.25, marking a -37.50% decrease from the reported $-3.6 in 2024. Estimates for the following years are $-1.66 in 2026, $-1.08 in 2027, $-0.49 in 2028, and $0.04 in 2029.

What is Twist Bioscience’s revenue forecast?

Twist Bioscience's average annual revenue forecast for its fiscal year ending in September 2025 is $373.27M, reflecting a 19.27% increase from the reported $312.97M in 2024. The forecast for 2026 is $438.47M, followed by $522.91M for 2027, $605.5M for 2028, and $708.05M for 2029.

What is Twist Bioscience’s net income forecast?

Twist Bioscience's net income forecast for the fiscal year ending in September 2025 stands at $-129M, representing a -38.24% decrease from the reported $-209M in 2024. Projections indicate $-96.838M in 2026, $-80.934M in 2027, $-28.138M in 2028, and $2.32M in 2029.